| ABOTALEB, Mariam, Peter KUBATKA, Martin CAPRNDA, Elizabeth VARGHESE, Barbora ZOLAKOVA, Pavol ZUBOR, Radka OPATRILOVA, Peter KRUŽLIAK, Patrik STEFANICKA and Dietrich BUSSELBERG. Chemotherapeutic agents for the treatment of metastatic breast cancer: An update. BIOMEDICINE & PHARMACOTHERAPY. Paris: ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, 2018, vol. 101, MAY 2018, p. 458-477. ISSN 0753-3322. Available from: https://dx.doi.org/10.1016/j.biopha.2018.02.108. |
Other formats:
BibTeX
LaTeX
RIS
@article{1419758,
author = {Abotaleb, Mariam and Kubatka, Peter and Caprnda, Martin and Varghese, Elizabeth and Zolakova, Barbora and Zubor, Pavol and Opatrilova, Radka and Kružliak, Peter and Stefanicka, Patrik and Busselberg, Dietrich},
article_location = {Paris},
article_number = {MAY 2018},
doi = {http://dx.doi.org/10.1016/j.biopha.2018.02.108},
keywords = {Metastatic breast cancer; Chemotherapy; Efficacy; Toxicity; Resistance; Antimetabolites; Immunologic therapy; Hormonal/endocrine therapy; DNA alkylating agents; Ion modulators; Antimitotic agents},
language = {eng},
issn = {0753-3322},
journal = {BIOMEDICINE & PHARMACOTHERAPY},
title = {Chemotherapeutic agents for the treatment of metastatic breast cancer: An update},
volume = {101},
year = {2018}
}
TY - JOUR
ID - 1419758
AU - Abotaleb, Mariam - Kubatka, Peter - Caprnda, Martin - Varghese, Elizabeth - Zolakova, Barbora - Zubor, Pavol - Opatrilova, Radka - Kružliak, Peter - Stefanicka, Patrik - Busselberg, Dietrich
PY - 2018
TI - Chemotherapeutic agents for the treatment of metastatic breast cancer: An update
JF - BIOMEDICINE & PHARMACOTHERAPY
VL - 101
IS - MAY 2018
SP - 458-477
EP - 458-477
PB - ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
SN - 07533322
KW - Metastatic breast cancer
KW - Chemotherapy
KW - Efficacy
KW - Toxicity
KW - Resistance
KW - Antimetabolites
KW - Immunologic therapy
KW - Hormonal/endocrine therapy
KW - DNA alkylating agents
KW - Ion modulators
KW - Antimitotic agents
N2 - Breast cancer is the second greatest cause of death among women worldwide; it comprises a group of heterogeneous diseases that evolves due to uncontrolled cellular growth and differentiation and the loss of normal programmed cell death. There are different molecular sub-types of breast cancer; therefore, various options are selected for treatment of different forms of metastatic breast cancer. However, the use of chemotherapeutic drugs is usually accompanied by deleterious side effects and the development of drug resistance when applied for a longer period. This review offers a classification of these chemotherapeutic agents according to their modes of action and therefore improves the understanding of molecular targets that are affected during treatment. Overall, it will allow the clinician to identify more specific targets to increase the effectiveness of a drug and to reduce general toxicity, resistance and other side effects.
ER -
ABOTALEB, Mariam, Peter KUBATKA, Martin CAPRNDA, Elizabeth VARGHESE, Barbora ZOLAKOVA, Pavol ZUBOR, Radka OPATRILOVA, Peter KRUŽLIAK, Patrik STEFANICKA and Dietrich BUSSELBERG. Chemotherapeutic agents for the treatment of metastatic breast cancer: An update. \textit{BIOMEDICINE \&{}amp; PHARMACOTHERAPY}. Paris: ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, 2018, vol.~101, MAY 2018, p.~458-477. ISSN~0753-3322. Available from: https://dx.doi.org/10.1016/j.biopha.2018.02.108.
|
